GlaxoSmithKline Pakistan Poised For Significant Growth, Analysts Say

Islamabad: GlaxoSmithKline Pakistan Limited (GLAXO) is expected to see its share price rise by 36% to Rs610, according to analysts at JS Global who have initiated coverage on the pharmaceutical company with a “Buy” rating. The projection is based on impressive financial performance and attractive market valuation.

JS Global cites a remarkable 3.6-fold year-over-year earnings increase over the last four quarters as a key driver of their optimistic outlook. This growth is anticipated to continue in the double digits, fueled by price adjustments, especially in GLAXO’s non-essential product portfolio, which makes up roughly half of its sales mix. The deregulated segment is also predicted to make a substantial contribution to earnings.

Profitability is likely to be further enhanced by falling Active Pharmaceutical Ingredient (API) costs. The price of Amoxicillin, a crucial ingredient in leading antibiotics, has dropped by over 40% this year. Combined with a debt-free balance sheet leading to minimal financial expenses, this positions GLAXO for one of the highest net profit margins in the industry.

The stock’s current valuation also presents an attractive entry point for investors. Its price-to-earnings growth (PEG) ratio is 0.5x, significantly lower than its historical average of 1.09x. Furthermore, its relative price-to-earnings ratio compared to the market stands at 1.8x, a discount to its 10-year average of 2.8x.

However, JS Global also acknowledges potential risks. Unfavorable regulatory changes regarding non-essential drug deregulation, weaker than anticipated sales volume growth, and currency depreciation could all negatively impact GLAXO’s performance.